Aarti Drugs Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: AARTIDRUGS BSE: 524348

₹430.90

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #65 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Aarti Drugs Limited (this stock)	3,933	22.9	12.6%	-11.7%	0.46%	67	59	51

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹4,349 Cr

EV / EBITDA

15.1x

EV / Sales

1.84x

Market cap / Sales

1.66x

Earnings yield

4.36%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 628 Cr, up 20.4% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	627	68	51	₹5.5700
March 31, 2026	632	59	45	₹4.9300
Dec. 31, 2025	529	22	34	₹3.7100
Sept. 30, 2025	579	56	42	₹4.5800
June 30, 2025	521	45	49	₹5.3300
March 31, 2025	623	71	61	₹6.7400
Dec. 31, 2024	515	52	39	₹4.2200
Sept. 30, 2024	543	41	30	₹3.3300
June 30, 2024	493	35	27	₹2.9300
March 31, 2024	560	50	36	₹3.9300
Dec. 31, 2023	538	43	32	₹3.4400
Sept. 30, 2023	578	47	35	₹3.7500
June 30, 2023	592	53	40	₹4.2700

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	628	633	530	579	521	625	526	543	493	561	540	578	592
Operating revenue	627	632	529	579	521	623	515	543	493	560	538	578	592
Other income	0	1	1	0	0	2	11	0	0	1	2	1	1
Operating expenses	536	552	486	504	457	534	454	484	439	490	478	512	520
Operating profit	92	79	42	75	64	89	60	60	54	69	60	65	72
Operating profit margin	14.6%	12.5%	8.0%	13.0%	12.3%	14.2%	11.7%	11.0%	11.0%	12.3%	11.1%	11.3%	12.2%
Depreciation	15	15	15	14	12	12	12	12	12	12	12	12	12
Interest	7	7	7	6	7	7	8	7	7	8	7	8	8
Exceptional items, gain / (loss)	-2	—	—	—	—	—	—	—	—	—	—	—	—
Profit before tax	68	59	22	56	45	71	52	41	35	50	43	47	53
Tax	17	14	-12	14	-3	9	14	10	8	14	11	12	14
Net profit	51	45	—	42	—	61	39	30	27	36	32	35	40
EPS	5.57	4.93	3.71	4.58	5.33	6.74	4.22	3.33	2.93	3.93	3.44	3.75	4.27
Net profit (TTM)	—	—	—	—	—	157	132	125	129	142	159	164	166
EPS (TTM)	18.79	18.55	20.36	20.87	19.62	17.22	14.41	13.63	14.05	15.39	17.20	17.72	17.92

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	2,260	181	169
March 31, 2025	2,174	199	157
March 31, 2024	2,267	192	142
March 31, 2023	2,498	205	153
March 31, 2022	2,251	256	195
March 31, 2021	1,915	338	258
March 31, 2020	1,635	175	136
March 31, 2019	1,454	128	87
March 31, 2018	1,160	112	73
March 31, 2017	1,160	112	73

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	-3.3%	3.3%	2,263^†	2,187^†	2,271^†	2,500^†	2,256^†	1,921^†	1,636^†	1,461^†	1,161^†	—
Operating revenue	-3.3%	3.4%	2,260	2,174	2,267	2,498	2,251	1,915	1,635	1,454	1,160	1,160
Other income	—	—	3^†	14^†	4^†	2^†	5^†	6^†	1^†	6^†	1^†	—
Operating expenses	—	—	2,000^†	1,911^†	2,001^†	2,216^†	1,933^†	1,514^†	1,390^†	1,255^†	978^†	—
Operating profit	-2.6%	-8.3%	261^†	263^†	266^†	282^†	318^†	401^†	244^†	199^†	182^†	—
Operating profit margin	—	—	11.5%^†	12.1%^†	11.7%^†	11.3%^†	14.1%^†	21.0%^†	14.9%^†	13.7%^†	15.7%^†	—
Depreciation	—	—	56^†	48^†	48^†	47^†	47^†	48^†	47^†	40^†	38^†	—
Interest	—	—	26^†	30^†	30^†	33^†	20^†	23^†	32^†	38^†	33^†	34^†
Exceptional items, gain / (loss)	—	—	0^†	0^†	0^†	0^†	0^†	0^†	8^†	0^†	0^†	0^†
Profit before tax	-4.0%	-11.7%	181	199	192	205	256	338	175	128	112	112
Tax	—	—	12^†	41^†	51^†	52^†	60^†	80^†	39^†	40^†	39^†	32^†
Net profit	3.5%	-8.1%	169	157	142	153	195	258	136	87	73	73
EPS	4.0%	-24.1%	18.55^†	17.22^†	15.39^†	16.50^†	21.04^†	73.62^†	58.17^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	11.5%^†	12.1%^†	11.7%^†	11.3%^†	14.1%^†	21.0%^†	14.9%^†	13.7%^†	15.7%^†	—
EBIT margin	9.2%^†	10.5%^†	9.8%^†	9.5%^†	12.2%^†	18.8%^†	12.7%^†	11.4%^†	12.5%^†	12.7%^†
PBT margin	8.0%	9.1%	8.5%	8.2%	11.3%	17.6%	10.7%	8.8%	9.7%	9.7%
Net margin	7.5%	7.2%	6.3%	6.1%	8.7%	13.5%	8.3%	6.0%	6.3%	6.3%
Interest coverage	7.88x^†	7.70x^†	7.38x^†	7.30x^†	13.74x^†	15.94x^†	6.44x^†	4.40x^†	4.40x^†	4.25x^†
Dividend payout	10.8%^†	5.8%^†	6.5%^†	6.1%^†	4.8%^†	3.4%^†	5.2%^†	—	—	—
Earnings retention	89.2%^†	94.2%^†	93.5%^†	93.9%^†	95.2%^†	96.6%^†	94.8%^†	—	—	—
Current ratio	1.70x	1.67x	—	—	—	—	—	—	—	—
Quick ratio	1.13x	1.10x	—	—	—	—	—	—	—	—
Debt to equity	0.30x	0.41x	—	—	—	—	—	—	—	—
Return on equity	12.0%	12.6%	—	—	—	—	—	—	—	—
Return on assets	7.1%	6.9%	—	—	—	—	—	—	—	—
Return on capital employed	12.4%^†	14.6%^†	—	—	—	—	—	—	—	—
Asset turnover	0.95x	0.96x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	254	-128	-126	102	152
March 31, 2025	220	-135	-85	137	83
March 31, 2024	337	-187	-149	189	148
March 31, 2023	162	-131	-31	131	32
March 31, 2022	40	-125	84	127	-87

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	2,382	1,405	1,314	238	182	1,213	713	4	970	405
March 31, 2025	2,273	1,251	1,160	276	238	1,181	706	3	760	407
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.